BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Nutrient Rich Organic products: Lift Your Wellbeing - 2The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- 3Medtronic has 'significant firepower' for multiple acquisitions, executives say
- 4RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- 56 Hints to Upgrade Your Appeal, In addition to Your Outlook
- Figure out How to Track and Anticipate Future Cd Rates
- Flash flooding causes highways to close to and from Eilat
- Potential Houthi threat to Red Sea shipping could further damage global economy
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Mount Everest Climbers 'Poisoned' by Guides Prompting Mass Helicopter Rescues in $20 Million Insurance Fraud Scheme, Police Say
- Russia’s New KVS Drone May Be Designed To Restore Reach In The FPV War
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
